中国实用妇科与产科杂志

• 论著 • 上一篇    下一篇

松奇贴片治疗围绝经期综合征124例疗效分析

龚莉莉1张绍芬1郁琦2陈蓉2阮祥燕3刘宏伟4胡丽娜4   

  1. 作者单位:1.复旦大学附属妇产科医院,上海 200011;2.中国医学科学院北京协和医院,北京 100730;3. 首都医科大学附属北京妇产医院,北京100026;4.四川大学华西第二医院,四川 成都610000
  • 出版日期:2015-06-02 发布日期:2015-07-05
  • 通讯作者: 郁琦

Efficacy of Estradiol Hemihydrate Patches used in 124 postmenopausal women.

GONG Li-li **,ZHANG Shao-fen**,YU QiCHEN RongRUAN Xiang-yanLIU Hong-weiHU Li-na.   

  1. *Obstetrics and Gynecology Hospital of Fudan University,Shanghai 200011,China
  • Online:2015-06-02 Published:2015-07-05

摘要:

目的 探讨半水合雌二醇贴片(商品名松奇)治疗围绝经期综合征的临床疗效。 方法 2009年12月至2011年6月应用多中心前瞻性研究方法在全国4家医院共纳入124例绝经后妇女,给予松奇贴片24周治疗,有子宫者加用孕激素,于治疗第4、12、24周检测血清雌二醇(E2)水平,并进行Kupperman评分以评价更年期症状,同时记录乳房胀痛、阴道流血和皮肤过敏等不良反应。结果 (1)生殖激素水平:E2在治疗前为(61.09±50.33)pmol/L,治疗4周时上升为(198.85±307.29)pmol/L(P=0.0003);治疗12周时进一步上升至(258.87±220.40)pmol/L(P=0.0001);治疗24周时 为(219.86±190.21)pmol/L(P=0.0000)。(2)Kupperman评分:治疗前Kupperman评分为23.91±8.11,治疗4周后,Kupperman评分较基线时大大下降,为9.05±7.56 (P=0.0000);治疗12周时,Kupperman评分又进一步下降,为5.73±5.42 (P=0.0000);治疗24周时,Kupperman评分基本维持不变,为5.76±7.03 (P=0.0000)。(3)研究期间未观察到严重副反应。结论 松奇贴片单独使用或加用口服微粒化孕酮或地屈孕酮能安全有效缓解围绝经期综合征。

关键词: 松奇贴片, 围绝期综合征, 绝经激素治疗

Abstract:

Abstract: Objective To investigate the clinical efficacy of Estradiol Hemihydrate Patches (Fem7) in menopausal women.Methods This multicenter(4 hospitals) prospective study enrolled a total of 124 cases of postmenopausal women,who received 24 weeks of Fem7. Progestin was added to those who had intact uterus. Changes in the serum levels of E2 and Kupperman Index were assessed on the time of visits (at the 4th week,the 12th week and the 24th week). Breast tenderness,vaginal bleeding and adverse reactions such as skin allergy were recorded simultaneously.Results (1) Serum levels of E2: Serum levels of E2 significantly increased with the treatment,(61.09±50.33)pmol/L (before treatment),(198.85±307.29)pmol/L(on the 4th week ,P=0.0003),(258.87±220.40)pmol/L(on the 12th week ,P=0.0001),(219.86±190.21)pmol/L(on the 24th week ,P=0.0000). (2) Kupperman Index : Kupperman Index significantly decreased with the treatment, 23.91±8.11 (before treatment),9.05±7.56(on the 4th week ,P=0.0000),5.73±5.42 (on the 12th week ,P=0.0000),5.76±7.03 (on the 24th week ,P=0.0000). (3)No serious side effects were observed during the study. Conclusion    Estradiol Hemihydrate Patches (Fem7) are well tolerated,providing rapid and effective relief of menopausal symptoms with or without oral micronized progesterone or dydrogesterone.

Key words: Estradiol Hemihydrate Patches , perimenopausal syndrome, menopausal hormone therapy

中图分类号: